Medication‐induced obstructive uropathy and hyperprolactinemia in a pediatric patient

Hyperprolactinemia can result from a pituitary tumor or decreased dopamine levels due to compression of the pituitary stalk. Hypothyroidism, renal failure, and drug interaction need to be ruled out as a part of diagnostic evaluation. The prolactin level often indicates the etiology, but drug interac...

Descripción completa

Detalles Bibliográficos
Autores principales: Nkansah‐Amankra, Kwabena, Sudhanthar, Sathyanarayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787808/
https://www.ncbi.nlm.nih.gov/pubmed/31624611
http://dx.doi.org/10.1002/ccr3.2396
_version_ 1783458359476748288
author Nkansah‐Amankra, Kwabena
Sudhanthar, Sathyanarayan
author_facet Nkansah‐Amankra, Kwabena
Sudhanthar, Sathyanarayan
author_sort Nkansah‐Amankra, Kwabena
collection PubMed
description Hyperprolactinemia can result from a pituitary tumor or decreased dopamine levels due to compression of the pituitary stalk. Hypothyroidism, renal failure, and drug interaction need to be ruled out as a part of diagnostic evaluation. The prolactin level often indicates the etiology, but drug interaction needs to be ruled out mainly in a patient who is on multiple medications.
format Online
Article
Text
id pubmed-6787808
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67878082019-10-17 Medication‐induced obstructive uropathy and hyperprolactinemia in a pediatric patient Nkansah‐Amankra, Kwabena Sudhanthar, Sathyanarayan Clin Case Rep Case Reports Hyperprolactinemia can result from a pituitary tumor or decreased dopamine levels due to compression of the pituitary stalk. Hypothyroidism, renal failure, and drug interaction need to be ruled out as a part of diagnostic evaluation. The prolactin level often indicates the etiology, but drug interaction needs to be ruled out mainly in a patient who is on multiple medications. John Wiley and Sons Inc. 2019-08-29 /pmc/articles/PMC6787808/ /pubmed/31624611 http://dx.doi.org/10.1002/ccr3.2396 Text en © 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Nkansah‐Amankra, Kwabena
Sudhanthar, Sathyanarayan
Medication‐induced obstructive uropathy and hyperprolactinemia in a pediatric patient
title Medication‐induced obstructive uropathy and hyperprolactinemia in a pediatric patient
title_full Medication‐induced obstructive uropathy and hyperprolactinemia in a pediatric patient
title_fullStr Medication‐induced obstructive uropathy and hyperprolactinemia in a pediatric patient
title_full_unstemmed Medication‐induced obstructive uropathy and hyperprolactinemia in a pediatric patient
title_short Medication‐induced obstructive uropathy and hyperprolactinemia in a pediatric patient
title_sort medication‐induced obstructive uropathy and hyperprolactinemia in a pediatric patient
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787808/
https://www.ncbi.nlm.nih.gov/pubmed/31624611
http://dx.doi.org/10.1002/ccr3.2396
work_keys_str_mv AT nkansahamankrakwabena medicationinducedobstructiveuropathyandhyperprolactinemiainapediatricpatient
AT sudhantharsathyanarayan medicationinducedobstructiveuropathyandhyperprolactinemiainapediatricpatient

Ejemplares similares